We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

IRAK

IRAK inhibitors act on interleukin-1 receptor-associated kinases (IRAKs), kinases of innate immune receptor signaling. IRAK was cloned in 1996 as a serine/threonine kinase that associates with the interleukin-1 (IL-1) receptor after stimulation. Mice lacking IRAK4 showed severe defects in IL-1 and Toll-like receptor signaling, which established a central role for this family member. The adaptor myeloid differentiation primary response 88 (MyD88) recruits IRAK4, which then phosphorylates IRAK1 on the route to nuclear factor kappa B activation. Emavusertib, listed as CA-4948, and IRAK inhibitor 4 target IRAK4, while IRAK-1-4 Inhibitor I blocks both IRAK1 and IRAK4. The list also contains compounds with other targets, such as the c-Jun N-terminal kinase inhibitor JNK-IN-7.

1 Item

  • IRAK-4 Peptide substrate
    Cat. No.
    A64908
    CAS No.
    2837877-90-2

    IRAK-4 Peptide substrate

    Synonyms: IRAK-1 (360-380)

    IRAK-4 Peptide substrate (IRAK-1 residues 360-380) is a bioactive peptide specifically designed to serve as a substrate for Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4). This peptide facilitates the study of IRAK-4's role in signal transduction pathways associated with inflammatory responses. It is suitable for applications in cellular signaling research, particularly in the context of immune system studies and cytokine signaling.

    In stock View Details
    1 mg
    $55.00
    5 mg
    $150.00
    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...